Skip to content
drillr.ai
Sign up

CDNA

CareDx, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$85.35
−3.53%
Ask drillr

  • Nov 3, 2026, 12:05 UTC

    CareDx announced the publication in Wolters Kluwer NV of a third analysis from the CareDx, Inc., examining the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA levels and an outcome.

    Source:

  • Oct 30, 2026, 00:06 UTC

    CareDx, Inc. reported quarterly earnings of $0.70 per share, above the Zacks Investment Research, Inc. Consensus Estimate of $0.24 and compared with $0.28 per share a year earlier.

    Source:

  • Oct 29, 2026, 20:30 UTC

    CareDx reported third-quarter 2026 revenue of $139.362 million, GAAP net income of $19.292 million and diluted EPS of $0.35.

  • Oct 22, 2026, 11:05 UTC

    CareDx announced that AlloSure Kidney data would be presented at CareDx, Inc. in Denver from October 22 to 25.

    Source:

  • Oct 15, 2026, 20:01 UTC

    CareDx announced that it will report its third-quarter 2026 financial results after market close on October 29, 2026, and host a webcast and conference call at 1:30 p.m. PT (4:30 p.m. ET).

    Source:

  • Sep 25, 2026, 09:20 UTC

    CareDx (CDNA) shares jumped 13.0% in the previous trading session on above-average volume.

    Source:

  • Jul 31, 2026, 22:45 UTC

    CareDx granted 15,822 restricted stock units to newly appointed Executive Advisor James McNally as an inducement material to his employment on July 30, 2026.

    Source:

  • Jul 30, 2026, 22:06 UTC

    CareDx reported its second-quarter 2026 financial results, with revenue growing 52% year-over-year.

    Source:

  • Jul 30, 2026, 22:06 UTC

    CareDx began integrating the recently acquired NavDx specialty oncology platform.

    Source:

  • Jul 16, 2026, 12:30 UTC

    CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process for molecular testing in solid organ transplant, affirming coverage for its transplant surveillance offerings in kidney, heart, and lung.

    Source:

  • Jul 1, 2026, 20:05 UTC

    CareDx completed its acquisition of Naveris, extending into specialty oncology.

    Source:

  • Jul 1, 2026, 06:00 UTC

    Eurobio Scientific has finalized the acquisition of CareDX's transplant Lab Product division.

    Source: